Ballew Advisors Inc Takes $205,000 Position in Johnson & Johnson (NYSE:JNJ)

Ballew Advisors Inc bought a new position in Johnson & Johnson (NYSE:JNJ) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 1,288 shares of the company’s stock, valued at approximately $205,000.

A number of other hedge funds have also recently modified their holdings of the stock. Morgan Stanley raised its stake in Johnson & Johnson by 4.3% in the 3rd quarter. Morgan Stanley now owns 22,472,765 shares of the company’s stock worth $3,345,745,000 after acquiring an additional 933,976 shares during the last quarter. California Public Employees Retirement System raised its stake in Johnson & Johnson by 8.9% in the 3rd quarter. California Public Employees Retirement System now owns 10,616,780 shares of the company’s stock worth $1,580,626,000 after acquiring an additional 864,547 shares during the last quarter. Boston Partners raised its stake in Johnson & Johnson by 16.1% in the 3rd quarter. Boston Partners now owns 6,862,037 shares of the company’s stock worth $1,021,620,000 after acquiring an additional 949,327 shares during the last quarter. Ninety One UK Ltd raised its stake in Johnson & Johnson by 5.7% in the 3rd quarter. Ninety One UK Ltd now owns 5,827,983 shares of the company’s stock worth $867,670,000 after acquiring an additional 313,670 shares during the last quarter. Finally, Raymond James & Associates raised its stake in Johnson & Johnson by 0.5% in the 3rd quarter. Raymond James & Associates now owns 3,688,170 shares of the company’s stock worth $549,100,000 after acquiring an additional 17,275 shares during the last quarter. Institutional investors own 61.26% of the company’s stock.

JNJ stock opened at $157.89 on Thursday. The company has a current ratio of 1.48, a quick ratio of 1.24 and a debt-to-equity ratio of 0.51. Johnson & Johnson has a 12-month low of $109.16 and a 12-month high of $161.32. The stock has a market cap of $415.65 billion, a price-to-earnings ratio of 24.83, a PEG ratio of 3.30 and a beta of 0.68. The business’s 50-day moving average is $152.86 and its 200 day moving average is $148.31.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Sunday, October 18th. The company reported $2.20 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.98 by $0.22. Johnson & Johnson had a net margin of 21.01% and a return on equity of 34.64%. The business had revenue of $21.08 billion for the quarter, compared to analyst estimates of $20.15 billion. During the same period last year, the company posted $2.12 EPS. The business’s revenue was up 1.7% on a year-over-year basis. As a group, equities analysts forecast that Johnson & Johnson will post 7.99 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 9th. Shareholders of record on Tuesday, February 23rd will be paid a $1.01 dividend. This represents a $4.04 dividend on an annualized basis and a yield of 2.56%. The ex-dividend date of this dividend is Monday, February 22nd. Johnson & Johnson’s dividend payout ratio (DPR) is 46.54%.

In other Johnson & Johnson news, COO Michael E. Sneed sold 54,662 shares of the firm’s stock in a transaction that occurred on Wednesday, December 9th. The shares were sold at an average price of $152.93, for a total value of $8,359,459.66. Following the transaction, the chief operating officer now directly owns 110,741 shares of the company’s stock, valued at approximately $16,935,621.13. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.27% of the company’s stock.

A number of equities analysts have weighed in on JNJ shares. Morgan Stanley lifted their price objective on Johnson & Johnson from $170.00 to $178.00 and gave the company an “overweight” rating in a research note on Tuesday, December 15th. Raymond James reiterated a “buy” rating on shares of Johnson & Johnson in a research note on Friday, November 20th. BidaskClub upgraded Johnson & Johnson from a “strong sell” rating to a “sell” rating in a research note on Wednesday, January 6th. Cantor Fitzgerald lifted their price objective on Johnson & Johnson from $168.00 to $180.00 and gave the company an “overweight” rating in a research note on Wednesday, October 14th. Finally, Credit Suisse Group lifted their price objective on Johnson & Johnson from $163.00 to $168.00 and gave the company an “outperform” rating in a research note on Wednesday, October 14th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and ten have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $165.50.

About Johnson & Johnson

Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.

Recommended Story: How to Calculate Compound Annual Growth Rate (CAGR)

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.